Earlier this year, scientist and soon-to-be physician Yentli Soto Albrecht spoke at the 12th Breakthrough Prize Ceremony. She was tasked with introducing neurogeneticist Rosa Rademakers, from the University of Antwerp, and neurologist Bryan Traynor, from the National Institutes of Health, who independently discovered in 2011 that a mutation called C9 repeat expansion is the most common genetic cause of amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD), two incurable neurodegenerative conditions.1,2
For Soto Albrecht, introducing these researchers meant more than just honoring their scientific contributions; as a carrier of the C9 mutation herself, she saw in their discovery a target for finding cures to diseases that affect many and could one day reach her too.
A Scientist. A Patient. A Doctor
In 2023, Soto Albrecht’s father was diagnosed with ALS. Up to that point, she and her relatives knew that their family had some history of neurodegenerative conditions, but they thought these were isolated incidents. “We didn't think that there was anything genetic running in our family,” said Soto Albrecht. That changed with her dad’s diagnosis, as his sister had also had ALS. “If two siblings in a generation have ALS, then it's probably genetic,” she said.

Scientist and physician-in-training Yentli Soto Albrecht leads efforts to find news therapies and preventive strategies for patients affected by genetic ALS and FTD, like herself.
Aurora Goldten-Appleton of PennMed Trainees Against ALS/FTD
One month after her father’s diagnosis, genetic testing identified him as a carrier of the C9 mutation. Soto Albrecht found that she also carried it a few months later. “My dad ended up being a really fast progressor, so I didn't even have room to process my own genetic tragedy,” she said. “I just kept that at the back of my mind and focused on helping him have the best year that he could.” After her father passed away, Soto Albrecht finished her graduate studies, which focused on mitochondrial function and viral infections. Motivated by her father’s diagnosis and her own condition, she redirected her attention as a physician-scientist in training to the neurodegenerative diseases that would come for her.
“I'm literally viewing the problem of two incurable diseases as of now and thinking: What does a solution need to look like in order to change the outcome for these patients?” she said.
Using AI to Search for ALS Targets
One of Soto Albrecht’s efforts was to assemble a team of researchers and students at the University of Pennsylvania (Penn), where she is training to become a physician, to apply for the Longitude Prize on ALS. This international program funds promising research projects that focus on finding drug targets for the condition.
Their project, which is called Penn Medicine Against ALS, won one of the awards. It centers on using AI to identify RNA-binding proteins that become dysregulated in ALS. The most well-studied protein in this group is the transactive response DNA binding protein 43 (TDP-43). Twenty years ago, scientists at Penn discovered that TDP-43 forms aggregates in neurodegenerative diseases.3 In ALS, more than 95 percent of the cases show TDP-43 dysfunction, suggesting that this protein is a key feature of the condition.4 “Our hypothesis is that there are other RNA-binding proteins, like TDP-43, that might also be dysregulated in ALS. We're trying to find those and target them,” explained Soto Albrecht, adding that they are using AI approaches to examine ALS patient datasets primarily available to the awardees but accessible to others upon request.
Finding a Cure for C9
Besides her RNA-binding protein research, Soto Albrecht also cofounded the CureC9 Program. This initiative created a scientific advisory board of experts in neurodegenerative diseases and drug development to identify promising research directions for treating and preventing ALS and FTD. Then, Soto Albrecht finds ways to turn these ideas into reality—whether that means connecting researchers across different institutions or finding ways to fund projects. “I'm specializing in reducing obstacles that scientists are facing in accomplishing the research that's important to save lives,” she said.

One of the projects supported by the CureC9 Program aims to develop a research platform that can categorize ALS and FTD patients based on biological differences, including ion metals that can be detected in tissues and cells using synchrotron beamlines.
Peter Cloetens
The first project the CureC9 Program is supporting is led by physician-scientist Claire Clelland at the University of California, San Francisco. Her team’s research focuses on optimizing delivery strategies for CRISPR-based gene editing therapies to enable them to reach the brain and spinal cord.
Clelland’s team will use physiologically maintained deceased people in their research. This involves brain-dead individuals kept under ventilation and blood circulation for a determined period of time. The researchers will study different barcoded gene therapy vehicles, and they will assess which ones best cross the blood-brain barrier and the types of cells the vehicles enter.5 “Instead of optimizing gene therapy vehicles in mice or monkeys, which has been done historically, she's optimizing everything in vivo,” Soto Albrecht said. “She can figure out any toxicity either in the [central nervous system] or in other tissues in a person and lower the risk towards putting those vehicles in a living person for an actual clinical trial.”
Recently, the CureC9 Program team began thinking about how to best design a prevention trial for genetic ALS and FTD, listing key criteria and determining targeted patient groups. “I just told [the] board, ‘We need to be testing drugs that are safe; that we have good evidence [that they] should work,’” said Soto Albrecht. “Once you advise me on what we're testing, then I'll find a way to fund it.”
The CureC9 Program and Longitude Prize on ALS project are just two examples of the 11 collaborative efforts Soto Albrecht has kickstarted related to this cause in less than two years. “I'm reducing barriers for other amazing people to innovate, or I'm bringing other amazing people together,” she said. “The goal is to cure incurable diseases. If we just keep our eye on the ball, I think we'll be able to move mountains a little faster.”
- Renton AE, et al. A hexanucleotide repeat expansion in C9ORF72 is the cause of chromosome 9p21-linked ALS-FTD. Neuron. 2011;72(2):257-268.
- DeJesus-Hernandez M, et al. Expanded GGGGCC hexanucleotide repeat in noncoding region of C9ORF72 causes chromosome 9p-linked FTD and ALS. Neuron. 2011;72(2):245-256.
- Forman MS, et al. TDP-43: a novel neurodegenerative proteinopathy. Curr Opin Neurobiol. 2007;17(5):548-555.
- Xu Z, Yang C. TDP-43-The key to understanding amyotrophic lateral sclerosis. Rare Dis. 2014;2(1):e944443.
- Pet DB, et al. Discovery research in physiologically maintained deceased. Science. 2025;388(6746):473-476.















